PL-5 trial reports better healing in mild infected burns; broader safety and use remain unresolved

A Burns & Trauma accepted manuscript published October 6 reports a Phase IIIb trial of peceleganan, also called PL-5, a synthetic antimicrobial peptide applied as a topical spray. A Chinese Academy of Sciences research release highlighted the paper on October 13. The publisher labels the manuscript accepted but not yet copyedited or typeset; that status matters when reading inconsistencies in the text.

The randomized, double-blind, placebo-controlled study took place at 23 centers in China. It enrolled adults aged 18 to 65 with mild infected burn wounds, with total burns covering no more than 10% of body surface area. Researchers randomized 348 participants: 232 to PL-5 and 116 to placebo. The results cannot be generalized to children, severe burns, chronic wounds or every person with a wound infection.

The primary endpoint was complete healing of the selected test wound on day 15. The reported analysis used 230 PL-5 participants and 116 placebo participants, rather than all 348 randomized participants. Healing was reported in 148 of 230 participants, or 64.3%, versus 50 of 116, or 43.1%. The paper reports a 21.2 percentage-point difference, with a 95% confidence interval of 9.8 to 31.3 percentage points.

The safety results report three serious adverse events among 231 treated PL-5 participants and one among 116 placebo participants. The authors judged these events unrelated to the study drug and reported no deaths. This differs from a later discussion sentence saying no serious adverse events were reported. Small event counts and short follow-up cannot rule out uncommon or longer-term harms.

Blood samples in the pharmacokinetic assessment were below the assay's lower limit of quantification. That supports no detectable blood concentration under the sampled conditions, not proof of zero absorption or absence of systemic risk. The authors identify limits including mild infections, exclusions affecting the patient population, baseline imbalances in burn depth and timing, and unresolved longer-term healing, recurrence and resistance outcomes.

The study received funding from Jiangsu Protelight Pharmaceutical & Biotechnology and Chinese public research programs; two listed authors have company affiliations. It compared PL-5 with placebo, not directly with every standard burn treatment. The paper is clinical research, not a marketing-approval notice or advice to buy or use a peptide product. No dosing or application instructions are provided, and these findings are not a reason to replace clinician-directed burn care.